In CAR-T cell therapy, clinicians obtain T cell source material directly from a patient (autologous), or from a donor (allogeneic), modify them, and re-introduce them to the patient. Working with autologous cells can be complicated by insufficient source material quality or quantity, and expanding the cells to the requisite number takes time that the patient may not have. Allogeneic cells can be prepared in advance and mass produced, but they may be rejected by the patient, and in the worst case, begin attacking the patient’s own cells.

Vladimir Senyukov is the Director of BioAnalytical Development at Precision Biosciences, where he investigates the development and manufacturing of allogeneic CAR-T cell products. We spoke to him about working with allogeneic CAR-T cells to unlock their therapeutic potential.

Using single-cell functional proteomics for CAR-T cell therapy development

Senyukov’s goal is to learn what actually drives a cell to be polyfunctional – to...

“My current project involves using IsoPlexis to profile the cytokine signatures of polyfunctional cells that we might have in a cell population,” said Senyukov. “Then we take those cells and employ a single cell RNA sequencing approach where we can also try to identify that polyfunctional cytokine signature in the RNAseq data. From there, we can try to identify what else—what other genes are associated with that signature—and then try to find the next genotype or other properties of a cell that makes them unique or different or better.”

Testing and verifying edited and engineered CAR-T cells

Whenever cells have been altered in the laboratory—especially on a genetic level— researchers need to ensure that the edits function as intended. “To test CAR-T cells and figure out if they function properly,” Senyukov said, “you usually test them against their targets.” Researchers use three common metrics to evaluate T cell function and response: “When T cells are activated, they produce cytokines for the microenvironment and make it more pro-inflammatory. They [recruit] other cells and make the target cells more sensitive for killing, and that’s one of the first responses usually from T cells when they encounter a target. The second way that a T cell responds is by killing, so we can measure how effectively CAR-T cells kill the target cells. The third expected response is that T cells will proliferate—when T cells recognize an antigen, they will increase the population of T cells that are responsive to that antigen.”

Single-cell functional proteomics is valuable here as well, explained Senyukov. “When optimizing, or when changing manufacturing processes to make better cells, it can be used to monitor cellular changes. It is especially valuable in screening for polyfunctionality, which is key, because based on the literature, polyfunctionality is one of the most important factors driving clinical efficiency.”

Unlocking the potential of allogeneic CAR-T cells

Ultimately, Senyukov would like to break new ground for allogeneic CAR-T cells, given that most of the existing research on polyfunctional T cells comes from cases of autologous cell transfer. “There haven’t been too many studies on the importance of polyfunctionality for allogeneic material, and there’s a need to find specific signatures that could give us information about functional efficiency in a particular patient group. It’s also about trying to find other pathways of gene expression associated with polyfunctionality that could allow future optimization of manufacturing processes.”

Meet the Sponsor:

This article is brought to you by IsoPlexis. IsoPlexis is dedicated to accelerating the fight against cancer and a range of our toughest diseases by producing the world’s most precise, award-winning detection systems.

Interested in reading more?

The Scientist ARCHIVES

Become a Member of

Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member?